Antonia Vlahou

Summary

Affiliation: Eastern Virginia Medical School
Country: USA

Publications

  1. ncbi Protein profiling in urine for the diagnosis of bladder cancer
    Antonia Vlahou
    Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
    Clin Chem 50:1438-41. 2004
  2. ncbi Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells
    Richard A Britten
    Department of Radiation Oncology, 600 Gresham Drive, Norfolk, VA 23507, USA
    Oncol Rep 14:1323-30. 2005
  3. ncbi Application of a novel protein chip mass spectrometry technology for the identification of bladder cancer-associated biomarkers
    Antonia Vlahou
    Department of Microbiology, Eastern Virginia Medical School, Virginia Prostate Center, Norfolk 23510, USA
    Adv Exp Med Biol 539:47-60. 2003
  4. ncbi Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1814-22. 2004
  5. ncbi Overexpression of alpha-defensin is associated with bladder cancer invasiveness
    Daniel A Holterman
    Departments of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Urol Oncol 24:97-108. 2006
  6. ncbi Sample preparation and bioinformatics in MALDI profiling of urinary proteins
    Panagiotis Zerefos
    Foundation for Biomedical Research of the Academy of Athens, Athens, Greece
    J Chromatogr B Analyt Technol Biomed Life Sci 853:20-30. 2007
  7. ncbi Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform
    Eric Schiffer
    Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany
    World J Urol 26:67-74. 2008
  8. ncbi Urine sample preparation and protein profiling by two-dimensional electrophoresis and matrix-assisted laser desorption ionization time of flight mass spectroscopy
    Panagiotis G Zerefos
    Division of Biotechnology, Biomedical Research Foundation, Academy of Athens, Athens, Greece
    Methods Mol Biol 428:141-57. 2008
  9. ncbi Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry
    Spiros D Garbis
    Biomedical Research Foundation, Academy of Athens, Greece
    J Proteome Res 7:3146-58. 2008

Collaborators

Detail Information

Publications9

  1. ncbi Protein profiling in urine for the diagnosis of bladder cancer
    Antonia Vlahou
    Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
    Clin Chem 50:1438-41. 2004
  2. ncbi Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells
    Richard A Britten
    Department of Radiation Oncology, 600 Gresham Drive, Norfolk, VA 23507, USA
    Oncol Rep 14:1323-30. 2005
    ..These data suggest that SELDI-based proteomic profiling may be useful in monitoring the emergence of cisplatin-resistant tumor cell clones...
  3. ncbi Application of a novel protein chip mass spectrometry technology for the identification of bladder cancer-associated biomarkers
    Antonia Vlahou
    Department of Microbiology, Eastern Virginia Medical School, Virginia Prostate Center, Norfolk 23510, USA
    Adv Exp Med Biol 539:47-60. 2003
  4. ncbi Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1814-22. 2004
    ..The authors also compared the plasma profiles of patients with cancer with the plasma profiles of healthy women to identify breast carcinoma-associated protein markers...
  5. ncbi Overexpression of alpha-defensin is associated with bladder cancer invasiveness
    Daniel A Holterman
    Departments of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Urol Oncol 24:97-108. 2006
    ..We propose that autocrine tumor expression of alpha-defensins may play an important role in facilitating the invasive phenotype of bladder cancer in patients...
  6. ncbi Sample preparation and bioinformatics in MALDI profiling of urinary proteins
    Panagiotis Zerefos
    Foundation for Biomedical Research of the Academy of Athens, Athens, Greece
    J Chromatogr B Analyt Technol Biomed Life Sci 853:20-30. 2007
    ..The importance of the presence of peak reproducibility filters when generating disease classification models is suggested...
  7. ncbi Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform
    Eric Schiffer
    Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany
    World J Urol 26:67-74. 2008
    ..In consequence, the necessity of repeated screening for reappearance demonstrates the urgent need for novel biomarkers as alternatives to invasive standard procedures...
  8. ncbi Urine sample preparation and protein profiling by two-dimensional electrophoresis and matrix-assisted laser desorption ionization time of flight mass spectroscopy
    Panagiotis G Zerefos
    Division of Biotechnology, Biomedical Research Foundation, Academy of Athens, Athens, Greece
    Methods Mol Biol 428:141-57. 2008
    ....
  9. ncbi Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry
    Spiros D Garbis
    Biomedical Research Foundation, Academy of Athens, Greece
    J Proteome Res 7:3146-58. 2008
    ..The PCa proteome found can serve as a useful aid for the identification of improved diagnostic and prognostic markers and ultimately novel chemopreventive and therapeutic targets...